Biocon submits intimation of early full redemption of NCDs

05 Jan 2026 Evaluate
Biocon has informed that this is further to intimation dated November 11, 2025 with regards to the outcome of the Board Meeting held on November 11, 2025 whereby the Board of Directors had approved early full redemption of 50,000 (Fifty Thousand) unlisted, secured, rated, redeemable Non-Convertible Debentures (‘NCDs’) of face value of Rs 1,00,000 each, aggregating to Rs 500 Crores, issued and allotted by the Company on private placement basis on May 19, 2023, subject to receipt of necessary approvals and / or consents on or before January 31, 2026. In this regard, the Company has made payment of due consideration today i.e. on January 05, 2026 as per agreement with concerned debenture holders and the debenture trustee towards the aforesaid early full redemption of 50,000 unlisted, secured, rated, redeemable NCDs. The above-mentioned information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

382.85 4.90 (1.30%)
09-Jan-2026 12:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1740.30
Dr. Reddys Lab 1211.00
Cipla 1460.65
Zydus Lifesciences 895.80
Lupin 2180.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×